Navigation Links
Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting

HUNTINGTON BEACH, California and AMSTERDAM, May 21 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple studies at the American Society of Clinical Oncology Annual Meeting, May 29 - June 2, 2009, in Orlando, Florida.

The study results further underpin the broad predictive and prognostic power of Agendia's breast cancer recurrence test MammaPrint(R) and highlight promising data on Agendia's new colon cancer recurrence test, ColoPrint(TM). Visitors can meet the Agendia team in booth #2014 and study results will be discussed at the following sessions:

    Date: Saturday, May 30, 2009
    Abstract #512
    Time: 5:00PM - 5:15PM
    Location: Level 2, West Hall D1
    The 70-gene profile and chemotherapy benefit in 1,600 breast cancer
    R. A. Bender, M. Knauer, E. J. Rutgers, A. M. Glas, F. A. de Snoo, S. C.
    Linn, L. J. Van 't Veer

    Date: Saturday, May 30, 2009
    Abstract # LBA515
    Time: 3:00PM - 6:00PM
    Location: Level 2, West Hall D1
    Breast cancer molecular profiles predict tumor response of neoadjuvant
    Doxorubicin and Taxol, the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)
    L. J. Esserman, C. Perou, M. Cheang, A. DeMichele, L. Carey, L. J. van 't
    Veer, J. Gray, E. Petricoin, K. Conway, D. Berry, I-Spy Investigators

    Date: Saturday, May 30, 2009
    Abstract #6570
    Time: 2:00PM - 6:00PM
    Location: Level 2, West Hall C
    Cost effectiveness of targeting chemotherapy with the 70-gene
    prognostic signature in early stage breast cancer (ESBC) patients
    K. B. Tong, E. Chen, G. Brink, R. Bender, F. de Snoo, J. Malin

    Date: Sunday, May 31, 2009
    Abstract #535
    Time: 8:00AM - 12:00PM
    Location: Level 2, West Hall D1, W240A
    Outcome prediction by the 70-gene profile in the context of the National
    Comprehensive Cancer Network (NCCN) guideline
    F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers,
    A. M. Glas, S. C. Linn, L. J. Van 't Veer

    Date: Sunday, May 31, 2009
    Abstract #4036
    Time: 8:00 AM - 12:00 PM
    Location: Level 2, West Hall C
    Development and validation of a robust prognostic and predictive
    signature for colorectal cancer (CRC) patients
    A. M. Glas, P. Roepman, R. Salazar, G. Capella, V. Moreno, J. Westerga,
    P. J. Kuppen, I. Simon, L. J. Van 't Veer, R. Tollenaar

    Date: Sunday, May 31, 2009
    Abstract #518
    Time: 8:00AM - 12:00PM
    Location: Level 2, West Hall D1, W240A
    Early determination of metastatic potential in breast cancer: the 70-gene
    signature in small tumors
    M. Knauer, S. Mook, V. Retel, M. Kok, J. Wesseling, A. M. Glas, E. J.
    Rutgers, L. J. van 't Veer, S. C. Linn

    Date: Monday, June 01, 2009
    Abstract #11083
    Time: 1:00PM - 5:00PM
    Location: Level 2, West Hall C
    Combining multi-gene profiling of molecular subtypes with the 70-gene
    profile for classification of breast cancer
    L. Stork-Sloots, O. Krijgsman, P. Roepman, F. A. de Snoo, R. A. Bender,
    A. M. Glas

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. The Company was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
2. Agendia Joins the Personalized Medicine Coalition (PMC)
3. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
4. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
5. Agendia BV Appoints Clinical and Scientific Advisory Board
6. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
9. Agendia Appoints New Chief Financial Officer
10. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
11. Agendia Appoints VP of Business Development
Post Your Comments:
(Date:11/24/2015)... INCLINE VILLAGE, Nev. , Nov. 24, 2015  PDL ... John P. McLaughlin , the company,s president and chief ... Piper Jaffray Healthcare Conference next week in New ... and will occur on Tuesday, December 1, 2015 at 9:30 ... and Presentations." Please connect to the website at least 15 ...
(Date:11/24/2015)... , Nov. 24, 2015 According to two ... in 2005. This is something that many doctors, scientists, and ... One questions remains: with fewer PSA tests being done, will ... Dr. David Samadi, "Despite the efforts ... disease remains the second leading cancer cause of death in ...
(Date:11/23/2015)... HONG KONG, Nov. 23, 2015 China Cord ... "Company"), China,s leading provider of cord blood collection, laboratory ... services, today announced its preliminary unaudited financial results for ... 2016 ended September 30, 2015. --> ... Highlights , Revenues for the second quarter of ...
(Date:11/23/2015)... The royalty-free a greement a llows ... 112 low- and m iddle-i ncome ... --> The Medicines Patent Pool (MPP) today announced its ... with Bristol-Myers Squibb for daclatasvir, a novel direct-acting antiviral that ... virus.  The royalty-free licence will enable generic manufacture of daclatasvir ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th until 19 th ... from 17 th until 19 th November 2015.   ... the first combined scanner in the world which scans both ... two different scanners were required: one for passports and one ... same surface. This innovation is an ideal solution for electronic ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
Breaking Biology News(10 mins):